Physician profile
Laura S Pace
NPI 1629267521
$2,591.53
in general payments reported to CMS, 2019-2025
18 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $336 · 2023: $316 · 2024: $1,002 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.32 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,140.93 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $268.88 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $196.19 | 2021-2025 | |
| Lilly USA, LLC | $172.07 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $132.86 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $114.71 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $103.09 | 2024-2025 | Dupixent |
| Ucb, INC. | $83.14 | 2024-2025 | Bimzelx |
| Pfizer INC. | $77.39 | 2021 | |
| Genzyme Corporation | $74.88 | 2021-2025 | |
| Merz North America, INC. | $64.72 | 2021-2024 | Xeomin |
| Galderma Laboratories, L.P. | $42.93 | 2021-2024 | |
| Janssen Biotech, INC. | $32.80 | 2022-2023 | Tremfya |
| Genentech USA, INC. | $30.96 | 2024 | Xolair |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.40 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.87 | 2023 | Spevigo |
| Vyne Pharmaceuticals INC. | $13.91 | 2021 | |
| Dermira, INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.